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PURPOSE. To determine if bone marrow-derived stem cell (BMSC) small extracellular vesicles
(sEV) promote retinal ganglion cell (RGC) neuroprotection in the genetic DBA/2J mouse
model of glaucoma for 12 months.
METHODS. BMSC sEV and control fibroblast-derived sEV were intravitreally injected into 3-
month-old DBA/2J mice once a month for 9 months. IOP and positive scotopic threshold
responses were measured from 3 months: IOP was measured monthly and positive scotopic
threshold responses were measured every 3 months. RGC neuroprotection was determined
in wholemounts stained with RNA binding protein with multiple splicing (RBPMS), whereas
axonal damage was assessed using paraphenylenediamine staining.
RESULTS. As expected, DBA/2J mice developed chronic ocular hypertension beginning at 6
months. The delivery of BMSC sEV, but not fibroblast sEV, provided significant neuroprotec-
tive effects for RBPMSþ RGC while significantly reducing the number of degenerating axons
seen in the optic nerve. BMSC sEV significantly preserved RGC function in 6-month-old mice,
but provided no benefit at 9 and 12 months.
CONCLUSIONS. BMSC sEV are an effective neuroprotective treatment in a chronic model of
ocular hypertension for 1 year, preserving RGC numbers and protecting against axonal
degeneration.
Keywords: glaucoma, DBA/2J, mesenchymal stem cells, extracellular vesicles, exosomes,
retinal ganglion cells
Glaucoma is a leading cause of irreversible blindness and ischaracterized by the degeneration of retinal ganglion cells
(RGC) and their axons. The most common type of glaucoma is
referred to as primary open-angle glaucoma, and its critical risk
factors include ocular hypertension, genetic predisposition,
and aging.1 Lowering IOP is currently the only treatment option
available, but it remains ineffective in many patients.2
Current research focuses on the development of neuropro-
tective strategies to prevent RGC death. Mesenchymal stem
cells (MSCs), a multipotent stromal cell, are currently being
tested in clinical trials due to having demonstrated efficacy in a
multitude of retinal disease models (reviewed in Ref. 3).4–7
Their mechanism of action was shown to be paracrine
mediated through the secretion of neurotrophic factors such
as nerve growth factor, brain-derived neurotrophic factor,8 and
platelet-derived growth factor,9 and more recently, exo-
somes.10,11
Exosomes are extracellular vesicles that are formed within
multivesicular bodies and released into the extracellular space
upon plasma membrane fusion.12 Exosomes contain miRNA,
mRNA, lipids, and proteins, and these contents are delivered
into the cytoplasm upon fusion with a recipient cell.13 The
delivered mRNA is then translated by the recipient cell,
whereas miRNA modulates gene expression. Thus, exosomes
are a potential novel cell communication mechanism. Micro-
vesicles, another class of extracellular vesicles, are formed
instead via outward budding of the plasma membrane.
Exosomes range between 40 and 150 nm, whereas microves-
icles are found ranging from 100 to 1000 nm; however, these
values vary greatly between studies, with some using the term
‘‘exosome’’ to encompass any extracellular vesicle isolated, and
others only referring to extracellular vesicles that pass through
a 220 nm filter. As a result of the heterogenous nature of the
vesicle preparation, small extracellular vesicle (sEV) is a more
accurate term and is used throughout the rest of the article.
MSC sEV have shown therapeutic efficacy in several disease
models including traumatic brain injury, stroke, and Alzheimer’s
disease (reviewed in Ref. 14). MSC sEV were shown to localize
specifically to the injured region of the spinal cord and
modulate M2 macrophages15 as well as direct the polarization
of macrophages from M1 to a M2 phenotype.16 In many cases,
the mechanism of therapeutic action for BMSC sEV appears to
be through the delivery of miRNA. For example, subcutaneous
delivery of MSC sEV promoted improvements in angiogenesis
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and cardiac function through miRNA-mediated mechanisms in
a mouse model of myocardial infarction.17 In a rat stroke
model, intravenous administration of MSC sEV and the delivery
of miRNA to neurons and astrocytes improved functional
recovery18 as well as the formation of neurons and oligoden-
drocytes and the suppression of phosphatase and tensin
homolog (PTEN) signaling.19 Intravenous administration of
sEV isolated from BMSC into rodent models of spinal cord
injury promoted a reduction in cellular apoptosis and
inflammation and an improvement in locomotor func-
tion.15,16,20 The neuroprotective efficacy of BMSC sEV on
RGC after optic nerve crush or ocular hypertension/glauco-
ma10,11 as well as their neuritogenic efficacy on cortical cells21
were attenuated if sEV miRNA were rendered dysfunctional
through the knockdown of argonaute-2 (AGO2) prior to sEV
isolation. AGO2 knockdown abrogates miRNA biogenesis,
function, and loading into vesicles as well as allows their
degradation.22,23 Several miRNA have been identified as
particularly abundant in BMSC sEV10 in comparison to sEV
derived from fibroblast, which are not RGC neuroprotective.9
We have previously demonstrated that BMSC sEV promote
neuroprotection in two short-term models of glaucoma: a laser
model and a microbead model.10 Delivery of the sEV into the
vitreous of rats promoted significant survival of RGC even
when injected once a month in a micro bead model during the
course of 2 months or a single injection in a laser model during
the course of 3 weeks. For future clinical application of
exosomes, it is important to test whether exosomes can
provide long-term neuroprotection in a chronic model of
glaucoma, such as in the DBA/2J genetic mouse model of
glaucoma, in which a prolonged rise in IOP occurs. Thus, the
purpose of this study is to demonstrate BMSC sEV efficacy in a
long-term glaucoma model using a monthly treatment regime
previously shown to be sufficient.
METHODS
Animals
A total of 60 adult, female, 3-month-old DBA/2J mice (Jackson
Laboratories, Bar Harbor, ME, USA) were maintained in
accordance with guidelines described in the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research
using protocols approved by the National Eye Institute
Committee on the Use and Care of Animals. Female mice
were chosen as they develop ocular hypertension sooner and
to a greater degree than males.24
Animals were kept at 218C/55% humidity under a 12-hour
light/dark cycle, were given food/water ad libitum, and were
under constant supervision from trained staff. Animals were
euthanized by rising concentrations of CO2 before dissection
of retinae and optic nerves.
Materials
All reagents were purchased from Sigma (Allentown, PA, USA)
unless otherwise specified.
BMSC Cultures
Human cluster of differentiation 29 (CD29)þ/CD44þ/CD73þ/
CD90þ/CD45 BMSC (confirmed by supplier; Lonza, Walkers-
ville, MD, USA) from 3 pooled donors were cultured in
Dulbecco’s modified eagle media (DMEM)/1% penicillin/
streptomycin/10% exosome-depleted fetal bovine serum (Ther-
mo Fisher Scientific, Cincinnati, OH, USA). Cell cultures were
maintained at 378C in 5% CO2 with medium changed every 3
days and cells passaged with 0.05% trypsin/EDTA when 80%
confluent. Human dermal fibroblasts (Lonza), which was used
as control cells were grown in the above conditions and used
as a control. For all experiments, BMSC and dermal fibroblasts
were used at passages 2 to 5.
Exosome/sEV Isolation and Quantification
Exosomes were isolated from BMSC and fibroblasts using a
polyethylene glycol (PEG) solution (ExoQuick-TC; System
Biosciences, Mountain View, CA, USA) per the manufacturer’s
instructions. Briefly, conditioned medium was centrifuged at
3000g for 15 minutes to remove cells and debris, incubated
with ExoQuick reagent overnight at 48C (1:10 ratio with
medium), and centrifuged at 1500g for 15 minutes before
resuspension of the exosome pellet in sterile phosphate-
buffered saline (sPBS). The exosome preparation is passed
through a 0.22 lm filter to remove any large extracellular
vesicles (microvesicles and apoptotic bodies). Because PEG
precipitation techniques are expected to yield some nonexo-
somal vesicles in the preparation, we thus refer to the
exosomes used in this study as sEV. The sEV were characterized
by their positive staining for the exosome/microvesicle
markers Syntenin-1 and CD63 and negative staining for high/
low density lipoprotein markers apolipoprotein A-1 (ApoA1)
and apolipoprotein B (ApoB) using Western blot as previously
detailed and reported.10 To ensure a consistent delivery
amount, sEV were quantified as detailed previously using a
NanoSight LM10 instrument (Malvern, Worcester, MA, USA).10
Briefly, for each sample we captured three videos and analyzed
them at a detection threshold of two 12.9- to 13.1-pix
maximum jump size, automatic blur size, and slider gain at
80 and with a total of 567 frames per video.
In Vivo Experimental Design
A total of 60 DBA/2J mice were separated into one of the
following three groups: Group 1 consisted of 20 untreated mice;
Group 2 consisted of 20 mice injected monthly with BMSC sEV;
Group 3 consisted of 20 mice injected monthly with fibroblast
sEV. Experiments began with 3-month-old mice, and they were
euthanized at 12 months. A total of 6 mice died toward the end
of the experiment, likely due to their old age in combination
with anesthesia. DBA/2J mice are known to suffer from colony-
specific problems including heart calcifications and thoracic
cavity malformations, which are expected to lead to sudden
death in a number of animals before the study concludes.25
The group with the smallest final count was 17 mice, and
the other two groups thus provided 17 mice randomly from
their cohort to maintain consistency. Because each eye
develops ocular hypertension independent of the contralateral
eye,25 they are thus treated as independent samples24 resulting
in 34 per group. RGC/axonal survival was assessed histolog-
ically whereas function was measured via electroretinography
(ERG). Optical coherence tomography was not performed as
images were of extremely poor quality, making analysis
unfeasible in aged DBA/2J mice due to the iris atrophy and
irregularly shaped pupil that was not amenable to tropicamide-
mediated dilation.25 Oculomotor response testing was not
conducted as DBA/2J mice show no response to these tests.26
Intraocular Pressure Recording (IOP)
IOP were recorded for all mice using a Tonolab rebound
tonometer (Colonial Medical Supply, Franconia, NH, USA). IOP
was recorded under isoflurane-induced anesthesia between 8
and 11 AM, sampled 18 times, and averaged for each individual
recording. Recordings were performed monthly from age 3 to
12 months and were taken just prior to the monthly intravitreal
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(ivit) injection. It is worth noting that DBA/2J mice are known
to develop corneal calcifications, making tonometry recording
of IOP unreliable.25 Indeed, previous studies demonstrate great
variation between IOP values recorded by tonometry versus
invasive measurements. Care was taken to avoid recording IOP
in obvious calcified regions while ensuring the probe point of
contact was perpendicular to the cornea; however, without
available invasive measuring techniques it can be assumed
reliability is inversely proportional to the age of the mice.
Ivit Delivery of sEV
Under isoflurane-induced anesthesia, sEV were injected into
the vitreous just posterior to the limbus using glass micropi-
pettes. A 2 ll volume of sPBS loaded with 1 3 109 sEV was
injected slowly, and the needle was retracted only after a 1-
minute delay to minimize backflow. The concentration was
chosen based on our previous studies10,11 that demonstrated
efficacy with the volume and concentration adapted for the
mouse vitreous volume. Injections were performed once a
month from 3 to 12 months.
ERG Measurements of the Positive Scotopic
Threshold Response
ERG was recorded using the Espion Ganzfeld full field system
(Diagnosys LLC, Lowell, MA, USA) on 3-month-old mice, before
any detectable ocular hypertension or functional decline,24,25,27
and on mice aged 6, 9, and 12 months, when RGC function is
expected to deteriorate. Mice were dark adapted for 12 hours and
prepared for ERG recording under dim red light (>630 nm).
Anesthesia was induced with intraperitoneal injection of
ketamine/xylazine, and the eyes were dilated with tropicamide.
Scotopic flash ERG was recorded from5.5 log (cd s) m2 to 1.0
log (cd s) m2 in 0.5 log unit increments. ERG traces were
analyzed using in built Espion software and the amplitude (with
respect to baseline) was used as a measure of mouse visual
function. Traces at a light intensity of 5.0 log (cd s) m2 were
chosen for analysis as they produced a clean, unambiguous
positive scotopic threshold response (pSTR) at approximately
100 milliseconds after stimulus, of which the peak amplitude was
recorded. Although it is possible that corneal calcifications may
have affected the RGC traces, it is expected this effect will be
universal for all groups and equally, we were still able to measure
pSTR in mice aged 12 months. All readings and analysis were
performed by an individual masked to the treatment groups.
Tissue Processing
Mice were euthanized at 12 months by rising concentration of
CO2 and immediately perfused intracardially with 4% parafor-
maldehyde in PBS. The eyes were enucleated and retinae
dissected and immersion postfixed in 4% paraformaldehyde for
1 hour at 48C. Optic nerves were dissected, cryopreserved in
10%, 2%0, and 30% sucrose solution in PBS for 24 hours at 48C.
Optic nerves were embedded in optimal cutting temperature
embedding medium (VWR International, Inc., Bridgeport, NJ,
USA) in peel-away mold containers (VWR International, Inc.)
and stored at808C. Optic nerves were coronally sectioned on a
CM1860 Cryostat microtome (Leica Microsystems, Inc., Ban-
nockburn, IL, USA) at208C at a thickness of 5 lm, mounted on
positively charged glass slides (Superfrost Plus, Fisher Scientific,
Pittsburgh, PA, USA), and stored at808C until required.
RGC Counts in Retinal Wholemounts
Retinal wholemounts were permeabilized by immersion in
0.5% Triton X-100 in PBS for 15 minutes at708C and washed
in fresh Triton X-100 for a further 15 minutes before incubation
with primary antibody diluted in wholemount antibody
diluting buffer (2% bovine serum albumin, 2% Triton X-100
in PBS) overnight at 48C. The following day, wholemounts
were washed for 3 3 10 minutes in PBS and incubated with
secondary antibodies in wholemount antibody diluting buffer
for 2 hours at room temperature. After 2 hours, retinae were
washed for 33 10 minutes in PBS and mounted vitreous side
up on Superfrost Plus glass slides, facilitated by 4 equidistant
cuts into the peripheral retina. The slides were allowed to air
dry before mounting in Vectorshield medium (Vector Labora-
tories, Peterborough, UK) and applying cover slips. The
antibodies used are detailed in the Table.
Retinal wholemounts were imaged using a Z1 Imager
epifluorescent microscope equipped with an Axiocam HRc
camera (Carl Zeiss, Inc., Thornwood, NY, USA) and RNA
binding protein with multiple splicing (RBPMS)þ cells were
counted in three 0.33 mm2 regions per retinal quadrant at 0.5,
1, and 1.5 mm from the optic nerve head. Counts were
conducted manually by an individual masked to the treatment
group. The mean number of RGC/image was derived from the
12 images, which made up 8.3% of the total retina (16 mm2)28
and was used to calculate RGC/mm2 with each group
consisting of 34 retinae from 17 mice.
Glaucomatous Damage Scaling in Optic Nerve
Section
Glaucomatous damage in the optic nerve was assessed as
previously described.24,29,30 Briefly, optic nerves were stained
in 1% paraphenylenediamine in 1:1 propanol/methanol for 30
minutes at room temperature, washed in ethanol, and allowed
to air-dry before being mounted in Permount (Thermo Fisher
Scientific). Paraphenylenediamine darkly stains the axoplasm
of damaged axons and optic nerves were graded as mild,
moderate, or severe damage by two investigators masked both
from the treatment group as well as each other’s grades.
Approximately 20 sections were analyzed per optic nerve. The
grading scale followed previous guidelines,24,29 but briefly,
mild represents optic nerves with less than 5% of damaged
axons and no gliosis, moderate represents optic nerves with
5% to 30% axonal loss and early gliosis, and severe represents
optic nerves with more than 50% axonal loss and prominent
gliosis. Because there is overlap, a third masked investigator
was used if the initial two investigators disagreed on the
grading.
TABLE. Antibodies Used in Immunohistochemistry (IHC) and Western
Blot (WB)
Antigen Dilution Supplier Catalogue No.
RBPMS 1:500 (IHC) Thermo Fisher #ABN-1376
Syntentin-1 1:1,000 (WB) Abcam #Ab133267
CD63 1:1,000 (WB) System Bio #Exoab-CD63-A1
ApoA1 1:1,000 (WB) Abcam #ab7613
ApoB 1:1,000 (WB) Abcam #ab20737
HSC70 1:5,000 (WB) Santa Cruz #sc-7298
Mouse IgG HRP 1:2,000 (WB) GE Healthcare #NA-931
Guinea pig IgG 546 1:400 (IHC) Thermo Fisher #A-11074
Mouse IgG HRP 1:2,000 (WB) GE Healthcare #NA-931
Rabbit IgG HRP 1:10,000 (WB) Cell Signalling #7074
RBPMS, RNA-binding protein with multiple splicing; CD63, cluster
of differentiation 63; ApoA1, apolipoprotein A-1; ApoB, apolipoprotein
B; HSC70, heat shock cognate 71 kDa protein; IgG, immunoglobulin;
HRP, horseradish peroxidase.
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Statistics
All statistical tests were performed using SPSS 17.0 (IBM SPSS,
Inc., Chicago, IL, USA), and data are presented as mean 6
standard error of the mean with graphs constructed using
Graphpad Prism 7.01 (Graphpad Prism, La Jolla, CA, USA). The
Shapiro-Wilkes test was used to ensure all data were normally
distributed before parametric testing using a one-way analysis
of variance with a Tukey post-hoc test. Graded optic nerves
were compared using Fisher’s exact test (2 3 3). Statistical
differences were considered significant at P values < 0.05.
RESULTS
DBA/2J Mice Spontaneously Develop Ocular
Hypertension
DBA/2J mice maintained normal IOP (10–12 mm Hg) between
3 and 6 months (Fig. 1). At 7 months, IOP increased
spontaneously to 13.6 6 0.5 mm Hg, 13.5 6 0.5 mm Hg,
and 14.4 6 0.5 mm Hg in untreated, BMSC-sEV-treated, and
fibroblast-sEV-treated DBA/2J mice, respectively. By 12 months,
IOP increased to 18.4 6 1.6 mm Hg, 19.3 6 1.7 mm Hg, and
19.9 6 1.5 mm Hg in untreated, BMSC-sEV-treated, and
fibroblast-sEV-treated DBA/2J mice, respectively. IOP did not
significantly differ between the three groups at any age,
suggesting that BMSC/fibroblast sEV do not affect IOP in DBA/
2J mice.
BMSC sEV Are Neuroprotective in DBA/2J Mice
Quantification of the number of RBPMSþ RGC at 12 months in
retinal wholemounts of BMSC-sEV-treated DBA/2J mice (962 6
116 RGC/mm2) was significantly higher (P < 0.001) than those
of fibroblast-sEV-treated mice (268 6 72 RGC/mm2) or
untreated mice (259 6 106 RGC/mm2; Fig. 2). Therefore,
BMSC sEV protect 3.7-fold greater numbers of RBPMSþ RGC
compared to untreated mice and demonstrates that BMSC sEV
are RGC neuroprotective in DBA/2J mice.
BMSC sEV Prevent RGC Functional Decline at 6
Months, but Not 9 or 12 Months
The amplitude of the pSTR was 47.3 6 2.1 lV in DBA/2J mice
aged 3 months (Fig. 3). By 6 months, pSTR amplitude in BMSC-
sEV-treated DBA/2J mice had decreased (33.2 6 3.0 lV) but
remained significantly higher than that in fibroblast-sEV-treated
mice (22.9 6 1.8 lV) or untreated mice (26.3 6 2.4 lV). By 9
and 12 months, pSTR amplitudes in BMSC-sEV-treated (24.9 6
2.4 lV and 19.7 6 2.6 lV, respectively), fibroblast-sEV-treated
(20.5 6 2.7 lV and 15.6 6 3.1 lV, respectively), and untreated
(18.5 6 2.2 lV and 16.1 6 3.2 lV, respectively) DBA/2J mice
had decreased further, but there was no longer a significant
difference between groups. These results demonstrate that
BMSC sEV prevent the early decline in RGC function, but
cannot prevent later decline in RGC function in DBA/2J mice.
Axonal Degeneration Data
The distribution of optic nerve damage, graded as mild,
moderate, and severe, was significantly (P < 0.01) skewed
more to the severe grading in untreated 12-month-old DBA/2J
mice (12%, 22%, 66%, respectively) and mice treated with
fibroblast-derived sEV (18%, 24%, 58%, respectively) compared
to BMSC-derived-sEV treated mice (33%, 37%, 40%, respective-
ly; Fig. 4). These results suggest that BMSC sEV reduces axonal
damage in DBA/2J mice.
DISCUSSION
The present study demonstrates that BMSC sEV do not affect
the development of spontaneous ocular hypertension in the
DBA/2J genetic mouse model of glaucoma, but protect RBPMSþ
RGC from death. The number of degenerating axons in the
optic nerve was also significantly diminished after BMSC sEV
treatment; however, RGC function deteriorated in all three
groups with BMSC sEV only providing a modest significant
effect at 6 months.
FIGURE 1. IOP measurements in DBA/2J mice. Mean (6 SEM) IOP
(mm Hg) of untreated animals and animals receiving ivit injection of
BMSC- or fibroblast-derived sEV. No significant difference (P > 0.05)
between untreated and experimental groups was found.
FIGURE 2. Surviving RBPMSþ RGC counts in DBA/2J mice. (A)
Quantification of the mean (6 SEM) number of surviving RBPMSþ
RGC in 12-month-old DBA/2J mice with or without ivit injection of
BMSC- or fibroblast-derived sEV. Asterisks indicate significant difference
between groups (P < 0.001). (B) Representative images of RBPMSþ
RGC from immunohistochemically stained retinal wholemounts (scale
bar: 100 lm).
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DBA/2J mice are a mouse model of glaucoma, specifically
pigmentary glaucoma. Mutations in tyrosinase-related protein 1
and glycosylated protein nmb lead to iris stromal atrophy and
iris pigment dispersion, respectively.31 A buildup of pigment
and cell debris in the trabecular meshwork overtime attenuates
drainage of aqueous humor, leading to a chronic rise in IOP.
Because DBA/2J mice are a mouse strain that spontaneously
develop ocular hypertension, they avoid complications arising
in other glaucoma models that require physical interventions
to elevate IOP. These complications include inflammatory
response to injections, lasers, and sutures; short duration
elevations in IOP; and an ocular hypertension detached from
the effects of age unlike what is seen in humans. A meta-
analysis of 1400 DBA/2J mice demonstrated that the initial
significant IOP elevation begins at 6 months and peaks at 10 to
12 months.24 An analysis of 772 nerves demonstrates that 10%
to 20% of nerves show a degenerative phenotype at 6 months,
whereas at 12 months, 60% to 80% of optic nerves were
degenerated. At 16 to 19 months, 80% of optic nerves were
degenerated.
Because pressure is uniform throughout the eye, it might be
expected that RGC die uniformly, but this is not what is seen.32
RGC display fan-shaped death, narrow at the optic head with
the zone devoid of RGC widening as it radiated out to the
periphery.32,33 This is seen in the human condition, likely due
to the compression of axonal bundles as they move through
the lamina cribrosa. Although lacking a lamina cribrosa, mice
do have a glial component that could elicit similar effects.34,35
Distinguishing through morphological differences, larger RGC
subtypes appear selectively resistant,32 which is similar to
other glaucoma and optic nerve injury models,36,37 although
limited studies exist to make strong conclusions. Thus, as in
the human condition, DBA/2J mice display an age-related rise
in IOP, a delay between the ocular hypertension and the
degeneration of RGC and their axons, and finally, a sectorial,
nonuniform pattern of death.
Clinical trials are already ongoing for the use of BMSC as a
treatment for several ocular diseases (reviewed in Ref. 3). Two
clinical trials have published reports on the efficacy and safety
of MSC sEV. The first demonstrated that systemic delivery of
MSC sEV improved kidney function and reduced inflammation
even 1 year after the treatment was delivered.38 The second
showed that delivery of MSC sEV into a patient with steroid
refractory graft-versus-host disease suppressed proinflamma-
tory cytokine secretion and reduced symptoms.39
Exosomes offer significant potential advantages over cell
therapy. First, because they are nondividing, they can be more
accurately dosed. They also likely avoid many of the
complications associated with transplanting dividing cells into
the eye including the retinal detachment and ocular hyperten-
sion reported in three patients receiving intravitreal adipose-
derived MSC and who subsequently went blind.40 Following
isolation, sEV can be stored for more than 6 months at 80C8
and also 2 weeks at 48C without loss of miRNA quantity or
function.41
Although the present study was not aimed at elucidating the
neuroprotective mechanism of BMSC sEV on RGC, our
previous studies are suggestive of a role for miRNA.10 Because
PEG precipitation isolates other vesicles along with exosomes
(hence our use of the term sEV) and other nonvesicle
structures, we must take care in drawing mechanistic
conclusions. For example, miRNA have been found associated
with protein aggregates (independent of sEV)42 as well as virus
particles,43 both of which are constituents of the PEG
precipitation along with sEV. Another negative effect of PEG
precipitation is that, although producing large yields of sEV, the
process can damage exosomes and impact on their biological
activity as well as the activity of their protein/nucleic acid
cargo.44 Despite similar neuroprotective efficacy in PEG-
isolated and ultracentrifugation-isolated BMSC sEV,11 we
cannot discount the fact that a suboptimal dose was being
injected into DBA/2J mice due to activity deficits associated
with the PEG isolation technique.
We observed a significant decline in RGC function as
measured by flash ERG and recording of the pSTR amplitude.
pSTR amplitude decreased from 47 lV at 3 months to 16 lV at
12 months. A previous study demonstrated similar functional
decline in female DBA/2J with pSTR amplitude decreasing
from 60 lV to 20 lV from 3 to 12 months.45 A second study
showed a larger decline in pSTR, from 100 lV at 3 months to
70 lV, 50 lV, and 25 lV at 6, 9, and 12 months, respectively.25
The likely reason larger amplitudes were seen in the referenced
study compared to our present study are because of the higher
flash intensity used by the authors that would have subse-
FIGURE 3. ERG measurements of pSTR in DBA/2J mice. (Left) Mean (6 SEM) amplitude (lV) of pSTR measured by ERG at 3- (untreated healthy
baseline), 6- , 9-, and 12-month-old DBA/2J mice with or without ivit injection of BMSC- or fibroblast-derived sEV. Asterisk indicates significant
difference between BMSC-derived sEV treated mice and fibroblast-derived sEV treated/untreated mice (P < 0.05). (Right) Representative traces of
pSTR; red arrows indicate the peak amplitude that was measured.
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quently activated bipolar cells and led to the incorrect
incorporation of a partial b-wave along with the pSTR in the
amplitude measurements. The functional decline beginning at
6 months, however, mirrors our present findings as well as the
scientific consensus that RGC functional decline is an early
effect occurring prior to any loss of RGC (reviewed in Refs. 46,
47). One curiosity with these results is the observation that
pSTR deficits are seen prior to significant ocular hypertension.
One possibility is that IOP had increased but not high or
consistently (considering IOP was recorded only once a
month) enough to produce a statistical significance. For
example, a separate study used a greater number of DBA/2J
mice and another technique to record RGC function known as
pattern ERG (PERG), which is reported to be more sensitive
and is able to detect early deteriorations in RGC function.
PERG showed RGC dysfunction beginning after 3 months in
DBA/2J mice and was inversely proportional to the rise in IOP,
that is, a rise of 1 mm Hg in IOP was seen per month (between
ages 2–6 months) with a contemporaneous decrease in PERG
amplitude by 1 lV.27 These increases in 1 mm Hg may have not
been detectable in the present study. These PERG experiments
demonstrated a complete abolition of responsiveness by 10 to
11 months in DBA/2J mice; however, it is worth noting that
PERG amplitudes are reversibly affected by simple postural
changes in the DBA/2J mouse.48
DBA/2J mice spontaneously developed ocular hypertension
with the elevated pressure beginning significantly at 6 months
as was also seen in previous studies.24 This is stereotypical of
female DBA/2J mice in comparison to males that develop
ocular hypertension beginning significantly at 7–8 months.
This is an exaggerated form of normal elevations in IOP as a
mouse ages and is followed by deficiencies in axonal transport,
functional deterioration, and RGC loss.24,49 A deterioration in
optokinetic response, a visual reflex that allows the eyes to
track an object in motion while maintaining a stationary image,
has been reported in DBA/2J mice with age/IOP,49,50 whereas
the oculomotor reflex, a similar reflex to optokinetic response
but involving movement of the head, is absent even in healthy
(>3 month) DBA/2J mice.26
Although we did not quantify the number of RGC in healthy
DBA/2J mice (<3 months old; prior to any RGC loss), it is well
reported that approximately 2750 FluoroGold (FG)þ RGC are
found per mm2 in retinal wholemounts.51,52 RBPMS stains all
major subtypes of RGC and exclusively RGC in the retina.53
Colocalization experiments show more than 99% of RBPMSþ
cells in the retina double label with FG, suggesting that FGþ
and RBPMSþ cell populations in the retina are the same.54,55 By
12 months, the number of RGC had reduced significantly to
less than 300 RBPMSþ RGC per mm2 in both untreated mice
and mice receiving fibroblast-derived sEV, which resembles
other studies demonstrating less than 500 FGþRGC per mm2 in
10-month-old DBA/2J mice. About 1000 RBPMSþ RGC per mm2
survived in the retina of mice receiving BMSC-derived sEV (Fig.
2). Similar survival has been demonstrated with other
neuroprotective strategies, for example, ivit transplantation
of glial cell line-derived neurotrophic factor (GDNF)-loaded
microspheres promoted survival of 1000 to 1500 RGC at
similar time points.51
Despite the present study injecting human sEV into mice
vitreous humor monthly from 3 to 12 months of age, we did
not observe any evidence of ocular inflammation. This was
largely expected as several studies have demonstrated that
transplantation of human MSC does not elicit any inflammatory
complications,56,57 and no difference in the survival of the graft
is seen when comparing transplantations of rat MSC into either
inbred or outbred rat breeds.58 Considering that sEV are one
small part of MSC and their secretome, the previous data
strongly suggest that BMSC-derived sEV do not elicit any kind
of inflammatory rejection in the eye.
RGC death in DBA/2J mice is through apoptosis and occurs
through a pathway distinct from that responsible for the
degeneration of their axons. The knockdown of BAX or JUN
prevents loss of RGC, but does not prevent degeneration of
their axons.29,59 Although most control retina were sparsely
populated with RGC by 12 months, we did notice that some
DBA/2J mice displayed a wedge/patchy pattern of RGC death
beginning at the optic nerve head and projecting/widening
toward the periphery, as has been described previously.51
Given the substantial RGC death, this is unlikely to affect the
sampling technique used in this study, however, taking an
earlier time point may produce much more variably dense
retina and may require whole retinal counts for reliability. The
regions of RGC death show expression profiles distinct from
the nearby unaffected regions.33 This fan-shaped loss of RGC
has been suggested to be explained by a local injury to axonal
bundles as they pass through the lamina cribrosa.34 By using
FIGURE 4. Frequency distribution of glaucomatous optic nerve damage
in DBA/2J mice. (A) Frequency of damage, defined as mild, moderate,
or severe and represented as a percentage of the total number of
analyzed optic nerve sections from 12-month-old DBA/2J mice with or
without ivit injection of BMSC- or fibroblast-derived sEV. Asterisks
indicate significant difference between groups (P < 0.01). (B) Example
of a nerve stained with paraphenylenediamine and a 50 lm 3 50 lm
box delineating the magnification area for three representative images
(C) of mild, moderate, and severe classified optic nerve sections (scale
bar: 15 lm).
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well-established grading scales to assess optic nerve damage in
DBA/2J mice,24 we demonstrated that mice receiving BMSC-
derived sEV performed better on the grading scale, with less
nerves being classified as severe and more classified as mild or
moderate. Thus, although BMSC-derived sEV are neuroprotec-
tive for RGC, they also provide a protective effect on their
axons, possibly because the delivery of multiple miRNA via sEV
has the potential to interact with multiple neuroprotective
pathways that spare the soma and the axon.
In conclusion, the present proof-of-principle study demon-
strates efficacy of BMSC sEV during the course of a 1-year
period in an animal model of glaucoma. Although all previous
studies have been performed using rats and acute models of
ocular hypertension, the present study was carried out in mice
and during a time period more analogous to the human
condition, a necessary step toward clinical testing. Future
studies will be directed at further discovering the mechanism
of BMSC sEV action in the eye, determining the feasibility of
more tolerable administration modalities, and ensuring the
safety of sEV treatment into the eye of patients.
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